Elotuzumab Recombinant Human Monoclonal Antibody, Invitrogen™

Description

• Endotoxin level < 0.01EU/μg by LAL method Use a manual defrost freezer and avoid repeated freeze thaw cycles
• Store at 2 to 8 °C for one week
• Store at -20 to -80 °C for twelve months from the date of receipt
• Elotuzumab is a humanized IgG1 (Immunoglobulin G) monoclonal antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies
• Elotuzumab targets SLAMF7, also known as Signaling Lymphocytic Activation Molecule Family member 7, a cell surface glycoprotein
• Elotuzumab consists of the complementary determining regions (CDR) of the mouse antibody, MuLuc63, grafted onto human IgG1 heavy and kappa light chain frameworks
• Elotuzumab is produced in NS0 cells by recombinant DNA technology
• Elotuzumab has a theoretical mass of 148
• 1 kDa for the intact antibody
• Elotuzumab was approved on November 30, 2015 by the U
• S
• Food and pharmaceutical Administration
• Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.